Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi/Regeneron’s PCSK9 Inhibitor Gets Reassuring CV Data – And A Priority Review Voucher

Related Content

Wary Of Surrogates, Payers Seek Outcomes Data For PCSK9 Class

Apr 01 2013

Preparing For Battle: PCSK9 Sponsors Stake Their Ground

Apr 07 2014

BioMarin Tests FDASIA’s Pediatric Voucher Waters With <em>Vimizim</em> Approval

Feb 24 2014

Another Chance to Make Priority Review Vouchers Work

Aug 22 2012

Related Companies

Sanofi

Regeneron Pharmaceuticals, Inc.

Amgen, Inc.

BioMarin Pharmaceutical Inc.

Additional Topics

United States Clinical Trials BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window